Stocks News

LAST PRICE
141.9100
TODAY'S CHANGE (%)
Trending Down-0.0900 (-0.0634%)

Bid / Lots
125.0000/ 1
Ask / Lots
144.0000/ 7
Open / Previous Close
141.1700 / 142.0000
Day Range
Low 140.1700
High 142.3000
52 Week Range
Low 89.0400
High 148.3699
Volume
670,978
average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

Today
- Neurocrine Biosciences Insider Sold Shares Worth $4,138,436, According to a Recent SEC Filing, from 7 hours ago by MT Newswires
  7 hours ago by MT Newswires
  Companies Mentioned: NBIX
  04:47 PM EDT, 05/16/2024 (MT Newswires) -- Matt Abernethy, Chief Financial Officer, on May 14, 2024, sold 30,000 shares in Neurocrine Biosciences (NBIX) for $4,138,436. Following the Form 4 filing with the SEC, Abernethy has control over a total of ...
Yesterday
- DJ S&P 500 Futures Steady In Premarket Trading; Monday.Com, Nextracker Lead, from 7:31AM ET on Wednesday May 15, 2024 by Dow Jones
  7:31AM ET on Wednesday May 15, 2024 by Dow Jones
  Companies Mentioned: NBIX, MEDP, ALNY, FOUR, MNDY, NU, NXT
  
  This article was automatically generated by Barrons.com using technology from Automated Insights.
  
  With U.S. stock markets set to open in two hours, monday.com Ltd. (MNDY) was up 19.4% in pre-market trading, and Nextracker Inc. (NXT) was up 13.9%.
May 14, 2024
- Neurocrine Biosciences Presented Baseline Data from the CAHtalyst™ Program in CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ECE 2024, from 8:30AM ET on Tuesday May 14, 2024 by PR Newswire
  8:30AM ET on Tuesday May 14, 2024 by PR Newswire
  Companies Mentioned: NBIX
  CAHtalyst™ Phase 3 Baseline Characteristics Highlight Limitations of Current CAH Treatment Paradigm in Children, Adolescents and Adults- Phase 2 Study for Modified-Release Hydrocortisone in Adults with Adrenal Insufficiency Demonstrated Participants Achieved Physiological MorningCortisol Levels after 4 Weeks- Phase 3 Extension Study Data for Modified-Release Hydrocortisone in Adults with CAH Demonstrated Reduction in Median Daily Hydrocortisone Dose and an Increase in Responders at Levels ≤ 25 mg/day
- Neurocrine Biosciences Presented Baseline Data from the CAHtalyst(TM) Program in CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ECE 2024, from 8:30AM ET on Tuesday May 14, 2024 by Dow Jones
  8:30AM ET on Tuesday May 14, 2024 by Dow Jones
  Companies Mentioned: NBIX
  
  Crinecerfont is an investigational, oral, selective corticotropin-releasing factor type 1 receptor (CRF(1) ) antagonist being developed to reduce and control excess adrenal androgens through a glucocorticoid-independent mechanism for the treatment of congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency. Antagonism of CRF(1) receptors in the pituitary has been shown to decrease adrenocorticotropic hormone levels, which in turn decreases the production of adrenal androgens and potentially the symptoms associated with CAH. Our data demonstrate that lowering adrenal androgen levels enables lower, more physiologic dosing of glucocorticoids and thus could potentially reduce the complications associated with exposure to greater than normal glucocorticoid doses in patients with CAH.
- DJ Neurocrine Initiated at Outperform by Evercore ISI Group, from 5:26AM ET on Tuesday May 14, 2024 by Dow Jones
  5:26AM ET on Tuesday May 14, 2024 by Dow Jones
  Companies Mentioned: NBIX
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/NBIX/analyst-ratings
  
  (END) Dow Jones Newswires
  
  May 14, 2024 05:26 ET (09:26 GMT)

May 14, 2024
- Medpace Holdings Insider Sold Shares Worth $1,996,723, According to a Recent SEC Filing, from 4:25PM ET on Tuesday May 14, 2024 by MT Newswires
  4:25PM ET on Tuesday May 14, 2024 by MT Newswires
  Companies Mentioned: MEDP
May 13, 2024
- Biomarin Pharmaceutical Insider Sold Shares Worth $3,255,200, According to a Recent SEC Filing, from 4:14PM ET on Monday May 13, 2024 by MT Newswires
  4:14PM ET on Monday May 13, 2024 by MT Newswires
  Companies Mentioned: BMRN
- Qiagen Receives FDA Clearance for Clinical Use of Respiratory Infection Test, from 4:18AM ET on Monday May 13, 2024 by MT Newswires
  4:18AM ET on Monday May 13, 2024 by MT Newswires
  Companies Mentioned: QGEN
May 8, 2024
- Medpace Holdings Insider Sold Shares Worth $21,129,347, According to a Recent SEC Filing, from 4:54PM ET on Wednesday May 08, 2024 by MT Newswires
  4:54PM ET on Wednesday May 08, 2024 by MT Newswires
  Companies Mentioned: MEDP
- BioMarin to Present at the BofA Securities 2024 Health Care Conference on Wednesday, May 15 at 10:00am PT / 1:00pm ET, in Las Vegas, NV, from 8:01AM ET on Wednesday May 08, 2024 by PR Newswire
  8:01AM ET on Wednesday May 08, 2024 by PR Newswire
  Companies Mentioned: BMRN
May 7, 2024
- HC Wainwright Adjusts Price Target on Alnylam Pharmaceuticals to $400 From $395, Maintains Buy Rating, from 9:12AM ET on Tuesday May 07, 2024 by MT Newswires
  9:12AM ET on Tuesday May 07, 2024 by MT Newswires
  Companies Mentioned: ALNY
- Alnylam Issues 2023 Corporate Responsibility Report, from 8:00AM ET on Tuesday May 07, 2024 by Business Wire
  8:00AM ET on Tuesday May 07, 2024 by Business Wire
  Companies Mentioned: ALNY
May 6, 2024
- Biomarin Pharmaceutical Insider Sold Shares Worth $414,550, According to a Recent SEC Filing, from 4:47PM ET on Monday May 06, 2024 by MT Newswires
  4:47PM ET on Monday May 06, 2024 by MT Newswires
  Companies Mentioned: BMRN
May 4, 2024
- New Data for BioMarin's VOXZOGO(R) (vosoritide) for Multiple Growth-Related Conditions in Children Presented at Pediatric Endocrine Society (PES) Annual Meeting, from 4:00PM ET on Saturday May 04, 2024 by PR Newswire
  4:00PM ET on Saturday May 04, 2024 by PR Newswire
  Companies Mentioned: BMRN
May 3, 2024
- Medpace Holdings Insider Sold Shares Worth $6,553,671, According to a Recent SEC Filing, from 4:13PM ET on Friday May 03, 2024 by MT Newswires
  4:13PM ET on Friday May 03, 2024 by MT Newswires
  Companies Mentioned: MEDP

Neurocrine Biosciences Inc
NASDAQ:NBIXUnited States

Search Criteria

Today

Neurocrine Biosciences Insider Sold Shares Worth $4,138,436, According to a Recent SEC Filing, from 7 hours ago by MT Newswires

Yesterday

DJ S&P 500 Futures Steady In Premarket Trading; Monday.Com, Nextracker Lead, from 7:31AM ET on Wednesday May 15, 2024 by Dow Jones

May 14, 2024

Neurocrine Biosciences Presented Baseline Data from the CAHtalyst™ Program in CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ECE 2024, from 8:30AM ET on Tuesday May 14, 2024 by PR Newswire

Neurocrine Biosciences Presented Baseline Data from the CAHtalyst(TM) Program in CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ECE 2024, from 8:30AM ET on Tuesday May 14, 2024 by Dow Jones

DJ Neurocrine Initiated at Outperform by Evercore ISI Group, from 5:26AM ET on Tuesday May 14, 2024 by Dow Jones

Peers Headlines

May 14, 2024

Medpace Holdings Insider Sold Shares Worth $1,996,723, According to a Recent SEC Filing, from 4:25PM ET on Tuesday May 14, 2024 by MT Newswires

May 13, 2024

Biomarin Pharmaceutical Insider Sold Shares Worth $3,255,200, According to a Recent SEC Filing, from 4:14PM ET on Monday May 13, 2024 by MT Newswires

Qiagen Receives FDA Clearance for Clinical Use of Respiratory Infection Test, from 4:18AM ET on Monday May 13, 2024 by MT Newswires

May 8, 2024

Medpace Holdings Insider Sold Shares Worth $21,129,347, According to a Recent SEC Filing, from 4:54PM ET on Wednesday May 08, 2024 by MT Newswires

BioMarin to Present at the BofA Securities 2024 Health Care Conference on Wednesday, May 15 at 10:00am PT / 1:00pm ET, in Las Vegas, NV, from 8:01AM ET on Wednesday May 08, 2024 by PR Newswire

May 7, 2024

HC Wainwright Adjusts Price Target on Alnylam Pharmaceuticals to $400 From $395, Maintains Buy Rating, from 9:12AM ET on Tuesday May 07, 2024 by MT Newswires

Alnylam Issues 2023 Corporate Responsibility Report, from 8:00AM ET on Tuesday May 07, 2024 by Business Wire

May 6, 2024

Biomarin Pharmaceutical Insider Sold Shares Worth $414,550, According to a Recent SEC Filing, from 4:47PM ET on Monday May 06, 2024 by MT Newswires

May 4, 2024

New Data for BioMarin's VOXZOGO(R) (vosoritide) for Multiple Growth-Related Conditions in Children Presented at Pediatric Endocrine Society (PES) Annual Meeting, from 4:00PM ET on Saturday May 04, 2024 by PR Newswire

May 3, 2024

Medpace Holdings Insider Sold Shares Worth $6,553,671, According to a Recent SEC Filing, from 4:13PM ET on Friday May 03, 2024 by MT Newswires